CHICAGO–(BUSINESS WIRE)–Paul Burton, the CEO of ResQ Pharma, Inc., a biopharmaceutical company
focused on commercializing LipidRescue™ Therapy (LRT), which is a
treatment for various drug overdoses and poisonings is scheduled to
present at Biotech Showcase as part of the J.P. Morgan 35th Annual
Healthcare Conference Week in San Francisco. The presentation will take
place on Wednesday January 11, 2017 at 3:30 pm PT at the Hilton San
Francisco Union Square, 333 O’Farrell Street at the Ballroom Level. Mr.
Burton will be discussing ResQ Pharma’s plans to attain regulatory
market approval for LRT by 2018.
According to the Center for Disease Control and Prevention (CDC) 47,055
people died in 2014 from drug overdoses in the US. ResQ Pharma is
energized about the opportunity to better address the situation by
commercializing a life-saving therapy.
About LipidRescueTM Therapy (LRT)
ResQ Pharma’s lead product candidate is LRT, which refers to the
administration of a lipid emulsion with the intent of reducing the
life-threatening clinical manifestations of toxicity from excessive
doses of certain lipophilic drugs. It is already the opinion of the
American Heart Association and American College of Medical Toxicology
that where there is serious hemodynamic instability from local
anesthetic drugs with high lipid solubility, LRT is a reasonable
consideration for therapy, even if patient is not in cardiac arrest.
About ResQ Pharma
ResQ Pharma, Inc., is a biopharmaceutical company created to ensure
reliable, global use of LRT, a treatment for various lipophilic drug
overdoses and poisonings. For more information on ResQ Pharma, please
We are members of iBIO’s PROPEL,
Founders Circle, The
BUNKER and MATTER!
We are also a Qualified New Business Venture for the Illinois Investment
Tax Credit Program. DLA Piper, LLP provided legal counsel for the
About Paul Burton, J.D., M.B.A.
Mr. Paul Burton has served as the CEO of ResQ Pharma since July 2015. He
is a former investment banker having started his career in corporate
finance with Salomon Brothers / Salomon Smith Barney in New York City in
1998 upon completion of both law school and business school at the
University of Illinois at Urbana-Champaign. More recently he has worked
with several entrepreneurial ventures in healthcare. Mr. Burton is also
a former U.S. Regular Army Commissioned Officer (Infantry).
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as “believes,”
“potential,” “proposed,” “anticipates,” “expects,” “plans,” “intends,”
“may,” “could,” “might,” “will,” “should” or other words that convey
uncertainty of future outcomes to identify these forward-looking
statements. Forward-looking statements include statements regarding our
intentions, beliefs, analyses or current expectations concerning, among
other things: our expectations regarding the clinical effectiveness and
safety of our product candidates and results of studies; and the timing
of and our ability to obtain U.S. Food and Drug Administration or other
regulatory authority approval of, or other action with respect to, our
product candidates and advancing studies for LRT. Any forward-looking
statements in this press release speak only as of the date of this press